Fibrolamellar Cancer of the Liver
Conditions
Brief summary
Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare (0.05 per 100,000) subtype of primary liver cancer which predominantly affects younger patients, median age of diagnosis 22-23 years. In patients with advanced stage disease the prognosis is poor, and even with aggressive surgery the 5 year survival is less than 50%. Due to the very low incidence of FLC clinical trials are limited, and as these patients are excluded from most clinical trials there is a lack of consensus on the optimal systemic therapy to employ in this population group. There are a number of chemotherapy compounds that have been investigated although these are single-institutional case series and/or registry-based studies. The majority of published registry studies are based in the United States hence it is important to describe the patterns of treatment in Europe which has different regulatory approvals for access to therapeutics. Our aim is to run a European multisite registry study detailing the clinical course of \>100 patients with FLC that have received systemic therapy.
Interventions
PROCEDURERegistry of Therapy of patient's diagnosed with FibroLamellar
Registry of Therapy of patient's diagnosed with FibroLamellar
Sponsors
Imperial College London
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic confirmed diagnosis of FLC * Written informed consent will be required for the prospective cohort * Adults of \>18 years of age
Exclusion criteria
* Any non- histologic confirmed diagnosis of FLC * Participants with insufficient clinical/ follow up data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To describe the natural history and clinical outcomes of patients with Fibrolamellar carcinoma of the liver | 2 years | The following data will be outcomes of interest in this study: treatments received including compliance and tolerability, survival (overall and progress free survival), clinicopathological outcomes. Survival outcomes, response rates |
Outcome results
None listed